The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India 1 , 2 , 3 , 4 – 5 .
Since then, it has become dominant in some regions of India and in the UK, and has spread to …

The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and
South Africa 1 , 2 – 3 . It has since spread to many countries and is expected to rapidly become …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants
were first identified in the United Kingdom and South Africa, respectively, and have since …

The severe acute respiratory syndrome coronavirus 2 Omicron BA.1 sublineage has been
supplanted in many countries by the BA.2 sublineage. BA.2 differs from BA.1 by about 21 …

Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 lineages has led to the
emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The …

Severe cases of COVID‐19 are associated with extensive lung damage and the presence of
infected multinucleated syncytial pneumocytes. The viral and cellular mechanisms …

It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic
cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we …

Severe COVID‐19 is characterized by lung abnormalities, including the presence of syncytial
pneumocytes. Syncytia form when SARS‐CoV‐2 spike protein expressed on the surface of …

Coordinated local mucosal and systemic immune responses following severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection either protect against coronavirus …

The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and
South Africa 1 , 2 . It has in the meantime spread to many countries and is expected to rapidly …